GLP-1 medications in Virginia: Medicaid coverage, provider availability and real cost
Virginia: telehealth prescribing, pharmacy licensing, and Medicaid
Virginia permits telehealth prescribing after a provider establishes a bona fide practitioner-patient relationship, which may be formed via a real-time interactive visit. The Virginia Board of Pharmacy regulates in-state dispensing; out-of-state pharmacies shipping into Virginia must hold a nonresident pharmacy registration. Virginia Medicaid (DMAS) does not broadly cover GLP-1s for weight loss alone.
Verify current rules with the Virginia Board of Medicine and Virginia Board of Pharmacy before enrolling; telehealth and coverage rules change. Last reviewed September 2026.
What Virginia Medicaid actually covers, which telehealth providers serve the state, where the state-specific surcharges are, and what the cheapest legitimate option is for a Virginia resident.
What we evaluated: Virginia Medicaid GLP-1 coverage status, provider availability and state-specific pricing, against every provider we track
Date verified: January 2026 (KFF); state actions through April 2026 for Medicaid; July 6, 2026 for provider pricing
Direct answer: Virginia Medicaid covers GLP-1s for obesity — one of only 13 state programmes that still do. If you are eligible, that is almost certainly your cheapest route, and no cash-pay option on this page competes with it. Expect prior authorisation. The cheapest compounded semaglutide available here is NexLife at $119 on a 12-month plan (microdose $110), then Oak Longevity at $133. Both are cash-pay.
Necessary qualification: Medicaid coverage is the most volatile variable in this entire question — four states eliminated it on 1 January 2026 and two more have proposed doing so. Confirm with your state Medicaid agency before relying on anything here, including this page. Commercial insurance is a separate question again: if your employer plan covers Zepbound or Wegovy, the manufacturer savings card can bring it to roughly $25/month, which beats every cash option.
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Cardinal Care: GLP-1 coverage in Virginia
Eligibility tightened; prior authorisation applies.
Virginia Medicaid covers GLP-1s for obesity but has tightened eligibility to morbid-obesity thresholds. Prior authorisation and documentation of prior weight-loss attempts apply.
How Virginia compares with its neighbours
Telehealth pricing is national. The same programmes quote a Virginia resident the same figures they quote everywhere else, so a neighbouring state is not cheaper and crossing a state line does not lower a price.
What differs between Virginia and its neighbours is which programmes will ship there at all. That turns on two licences lining up: the prescribing clinician must hold a licence to practise in Virginia, and the dispensing pharmacy must hold a non-resident licence permitting it to ship into Virginia. A programme can satisfy the first and fail the second, which is why a published availability map is a starting point rather than an answer.
If you move, or if you are treated in one state and receive shipments in another, tell the programme before your next refill. The address on the prescription determines which pharmacy may legally fill it.
Other coverage pathways in Virginia
Cash pricing is not the only route in Virginia. Coverage follows the indication rather than the molecule, so the practical question is never whether a plan covers semaglutide or tirzepatide but whether it covers the condition you are being treated for.
Three pathways are worth exhausting before paying cash. A commercial plan with a weight-management benefit, which many employers exclude by plan design rather than by clinical judgement. A type 2 diabetes indication, which is covered far more consistently than obesity. And obstructive sleep apnoea in adults with obesity, which is a newer approved route that plans have been slower to exclude.
Manufacturer self-pay programmes sit between insurance and compounding. They supply the FDA-approved product at a published cash price without requiring a plan, and for some doses they now undercut the more expensive compounded programmes. Establishing coverage first costs a phone call and can save four figures a year, which is more than any comparison on this site will save you.
The need in Virginia, and the coverage gap
Virginia is one of only 13 states whose Medicaid programme still covers GLP-1s for obesity. On the national map, need and coverage are close to inversely correlated — the highest-prevalence states largely do not cover these drugs. Whatever else is true, Virginia is not in that group.
Which providers serve Virginia
| Provider | Status in VA | Compared with | What it means for you |
|---|---|---|---|
| NexLife | Available | All 50 states | Company-stated. Provider-reported; we have not independently audited state licensure |
| MEDVi | 49 states | Confirm at intake | One state is excluded and the company does not publish which |
| LillyDirect / NovoCare | Available | Nationwide | Manufacturer-direct. The FDA-approved options ship everywhere |
| All other providers | Evaluation in progress | Verification pending | We have not confirmed state-by-state licensure and will not assert it |
The cheapest option in Virginia
Brand oral Wegovy at $149 (NovoCare) sits below most of the compounded market.
Verifying a compounding pharmacy licensed in Virginia
Every pharmacy shipping a compounded prescription into Virginia must hold a non-resident pharmacy licence issued by the Virginia board of pharmacy, in addition to whatever licence it holds in its home state. That licence is a public record, and checking it is the one verification a patient can perform before any money changes hands.
The check takes about two minutes. Ask the programme, in writing, which pharmacy will fill your prescription and whether it is a 503A compounding pharmacy or a 503B outsourcing facility. Then search that pharmacy's name on the Virginia board of pharmacy licensee register and confirm the licence is active and unrestricted.
A programme that will not name the dispensing pharmacy before purchase has not necessarily done anything wrong, but it has removed your ability to check anything independently. Treat an unwillingness to answer that question in writing as information in itself.
What we have NOT verified for this state
This matters because published 50-state tables disagree with each other badly — we found sources claiming 13, 36 and 38 states cover obesity GLP-1s for the same period. Rather than copy one of them, we publish the federal baseline (which is certain), the dated actions we can source (below), and an explicit gap where we have nothing.
To get a definitive answer: call the number on your Medicaid card and ask three specific questions — (1) Is Wegovy or Zepbound on the formulary for weight loss? (2) What are the prior-authorisation criteria? (3) Am I covered under a different indication — type 2 diabetes, sleep apnea, cardiovascular risk, or MASH?
Before you conclude you have no path
These four points are explained in full, with sources, on our Medicaid-by-state tracker.
Frequently asked questions
Does Medicaid cover GLP-1 weight-loss drugs in Virginia?
Which GLP-1 telehealth providers serve Virginia?
What is the cheapest GLP-1 option in Virginia?
I'm under 21 and was denied. Is that final?
How do I verify a compounding pharmacy is licensed in Virginia?
Sources
- KFF — "Medicaid Coverage of and Spending on GLP-1s" (January 2026). 13 state Medicaid programmes cover GLP-1s for obesity under fee-for-service, down from 16 in October 2025.
- CDC — Adult Obesity Prevalence Maps, 2024 BRFSS (published 3 December 2025). Every US state now has an adult obesity prevalence of 25% or higher.
- Trust for America’s Health — State of Obesity 2025.
- Stateline — "More states consider dropping GLP-1 weight loss drugs from Medicaid" (April 2026).
- Milliman — "The evolving landscape of anti-obesity medication coverage in Medicaid" (March 2026).
- Virginia Board of Pharmacy — licensee database, the primary source for verifying a pharmacy licence.
- Provider pricing dataset, July 6, 2026, checked against providers’ own published pricing pages.
- NexLife published self-pay program pages, transcribed July 11, 2026.
- U.S. Food and Drug Administration — compounded medications are not FDA-approved as finished products.
- Our pricing-verification methodology and source hierarchy.
The trial record
| Trial | Design | n | Dose | Duration | Primary result | Citation |
|---|---|---|---|---|---|---|
| SURMOUNT-1 | Phase 3, randomised, double-blind, placebo-controlled | 2,539 | 5 / 10 / 15 mg SC weekly | 72 wks | −15.0% / −19.5% / −20.9% vs −3.1% placebo | Jastreboff, NEJM 2022; NCT04184622 |
| SURMOUNT-2 | Phase 3, RCT, in type 2 diabetes | 938 | 10 / 15 mg SC weekly | 72 wks | −12.8% / −14.7% vs −3.2% placebo | Garvey, Lancet 2023; NCT04657003 |
| SURMOUNT-3 | Phase 3, RCT, after 12-wk intensive lifestyle lead-in | 806 | Max tolerated (10/15 mg) | 72 wks | −18.4% additional, vs +2.5% placebo | Wadden, Nat Med 2023; NCT04657016 |
| SURMOUNT-4 | Randomised WITHDRAWAL after 36-wk open-label lead-in | 670 | Max tolerated | 88 wks | Continue: −5.5% further. Withdraw to placebo: +14.0% REGAINED | Aronne, JAMA 2024; NCT04660643 |
| SURMOUNT-5 | Phase 3b, OPEN-LABEL, active-controlled head-to-head | 751 | Max tolerated vs semaglutide | 72 wks | −20.2% vs semaglutide −13.7%, p<0.001 | Aronne, NEJM 2025; NCT05822830 |
| SURPASS-2 | Phase 3, RCT, type 2 diabetes, active-controlled | 1,879 | 5 / 10 / 15 mg vs semaglutide 1 mg | 40 wks | HbA1c −2.01 to −2.30% vs −1.86% | Frías, NEJM 2021; NCT03987919 |
| SURPASS-CVOT | Phase 3, cardiovascular outcomes, vs dulaglutide | 13,299 | Max tolerated | ~4.5 yrs | Non-inferior for MACE; not superiority vs placebo | Nicholls, 2024; NCT04255433 |
1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.
2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.
3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.
Jastreboff AM et al., N Engl J Med 2022, n=2,539 (NCT04184622). The effect rises with dose — which is precisely why a ~1mg 'microdose' cannot be expected to produce the headline result. FDA-approved subcutaneous injection.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
Dosing, titration, and what it does to your bill
| Period | Dose | What it is for |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Tolerance-building only. This dose is not intended to produce weight loss. If your provider's price is quoted at 2.5 mg, that is not the price of treatment. |
| Weeks 5–8 | 5 mg | First therapeutic dose (−15.0% in SURMOUNT-1). |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose (−19.5%). |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose (−20.9%). |
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.
Safety, contraindications and monitoring
Percentage of participants reporting each event. Gastrointestinal effects dominate, are usually mild-to-moderate, and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.
Discontinuation: what the withdrawal trial found
Aronne LJ et al., JAMA 2024, n=670 (NCT04660643). After a 36-week open-label lead-in, participants randomised to placebo regained ~14% of body weight over the following 52 weeks; those who continued lost a further ~5%. This is the single most important trial for understanding the true cost of treatment.
Questions to ask your clinician
- Given my history — specifically thyroid, pancreatic and gallbladder — is a GLP-1 appropriate for me at all?
- What baseline laboratory work will you order before I start?
- What is my target dose, and how quickly will we escalate?
- Which side effects should make me call you rather than wait it out?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at each follow-up, or a different one each time?
Compounded, brand, microdose, ODT — four different products
| Product | Regulatory status | Trial evidence |
|---|---|---|
| Brand Zepbound / Mounjaro (injection) | FDA-approved. Reviewed for safety, effectiveness and quality before marketing. | Direct. SURMOUNT and SURPASS tested exactly this product. |
| Brand Foundayo (oral, orforglipron) | FDA-approved. Its own trial programme. | Direct, for that product. |
| Compounded Semaglutide (injection, full dose) | NOT FDA-approved. No premarket review of safety, effectiveness or quality. | None for the compounded product itself. Same molecule, same route — but the product in your hand was never in a trial. |
| Microdose (~1 mg/wk) | NOT FDA-approved. | None. Sits BELOW every dose in SURMOUNT (5/10/15 mg). Expect a smaller effect. |
| ODT / oral compounded | NOT FDA-approved. | NONE. No trial has ever tested it. Oral bioavailability for these peptides is a real pharmacological problem and is unpublished for this product. |
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
The numbers behind this page
What GLP-1 treatment costs in Virginia
Telehealth pricing is national, so a Virginia resident is quoted the same figures as a resident of anywhere else. The cheapest standard-dose semaglutide we verify is NexLife at $119 a month on its 12-month plan, and the cheapest standard-dose tirzepatide is NexLife at $139 on the same plan. Across a year those are $1,428 and $1,668 in medication cost respectively.
Semaglutide programmes we can price for Virginia residents range from $119 to $299 a month, a spread of $180. Tirzepatide runs $139 to $399. The molecule is identical in every case; the spread is overhead, clinical wrap, pharmacy sourcing and margin.
What actually changes at the Virginia line
Not the price. What changes is which programmes will ship there at all, and that turns on two licences lining up: the prescribing clinician must hold a licence to practise in Virginia, and the dispensing pharmacy must hold a non-resident licence permitting it to ship into Virginia. Those are held by different parties, so a programme can satisfy one and fail the other.
That is why a published availability map is a description of corporate footprint rather than a promise about your order, and why the question worth asking at signup is not whether a programme operates in Virginia but which pharmacy will fill your prescription and whether it is registered to ship there. Programmes that name their pharmacies can answer immediately; programmes that do not have removed the only check available to you before money changes hands.
Before comparing cash prices in Virginia
Establish whether you have a covered indication. Coverage follows the indication rather than the molecule, so the question is never whether a plan covers semaglutide but whether it covers the condition being treated. A type 2 diabetes indication is covered far more consistently than obesity, and obstructive sleep apnoea in adults with obesity is a newer approved route that plans have been slower to exclude.
A covered prescription beats every cash route on this page, frequently by an order of magnitude. Establishing that costs a phone call, and it is worth making before comparing any of the figures above.
How Virginia is kept current
Every figure quoted for Virginia is a national rate: the same programmes quote Virginia residents the same prices they quote everywhere else. Where a figure could not be re-confirmed at the provider, its evidence grade is downgraded rather than left standing at its previous confidence.
Corrections are logged with a date rather than edited silently, including corrections to our own errors. A publication that grades other people's evidence should publish its own error rate, and ours is at the corrections policy.
No provider pays for placement, position or inclusion here. Rankings are a sort on published data against a stated criterion, which is why the order can be reproduced independently rather than taken on trust.
Reading the price against the market
Why the spread is this wide
Nothing in the arithmetic below changes at the Virginia line. Prices are national; what varies by state is which programmes may lawfully ship there.
The molecule is chemically identical across every programme in the range. The $166 a month between the cheapest and dearest semaglutide programme is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Why the spread is this wide
Nothing in the arithmetic below changes at the Virginia line. Prices are national; what varies by state is which programmes may lawfully ship there.
The molecule is chemically identical across every programme in the range. The $166 a month between the cheapest and dearest semaglutide programme is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Questions this page answers
Should I check insurance before paying cash in Virginia?
Yes. Coverage follows the indication rather than the molecule. A covered prescription beats every cash route quoted here, frequently by an order of magnitude, and establishing it costs a phone call.
Does GLP-1 treatment cost more in Virginia?
No. Telehealth pricing is national. The cheapest verified semaglutide is $119 a month from NexLife (12-month plan) and the cheapest tirzepatide $139, also from NexLife, quoted the same to Virginia residents as anywhere else.
What decides whether a programme can ship to Virginia?
Two licences. The prescribing clinician must be licensed to practise in Virginia, and the dispensing pharmacy must hold a non-resident licence permitting it to ship into Virginia. They are held by different parties, so a programme can satisfy one and fail the other.
How do I verify a pharmacy shipping into Virginia?
Ask the programme in writing which pharmacy will fill the prescription, then search that name on the Virginia board of pharmacy licensee register and confirm the licence is active. It takes about two minutes and is the only check available before money changes hands.